Zacks: Brokerages Expect Trillium Therapeutics Inc (TRIL) to Announce -$0.40 Earnings Per Share

Wall Street brokerages expect Trillium Therapeutics Inc (NASDAQ:TRIL) (TSE:TR) to post earnings per share (EPS) of ($0.40) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Trillium Therapeutics’ earnings. Trillium Therapeutics reported earnings per share of ($0.51) in the same quarter last year, which would suggest a positive year-over-year growth rate of 21.6%. The firm is expected to issue its next earnings report on Friday, May 10th.

On average, analysts expect that Trillium Therapeutics will report full-year earnings of ($1.93) per share for the current financial year, with EPS estimates ranging from ($2.43) to ($1.67). For the next year, analysts forecast that the company will post earnings of ($1.44) per share, with EPS estimates ranging from ($1.61) to ($1.27). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that cover Trillium Therapeutics.

Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) last released its earnings results on Monday, March 11th. The biotechnology company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.24.

Several equities analysts have recently commented on TRIL shares. HC Wainwright lowered their price target on shares of Trillium Therapeutics from $10.00 to $4.00 and set a “buy” rating for the company in a research report on Wednesday, March 13th. Zacks Investment Research upgraded shares of Trillium Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a research report on Thursday. Finally, ValuEngine upgraded shares of Trillium Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd.

Several institutional investors have recently added to or reduced their stakes in the company. Morgan Stanley grew its holdings in Trillium Therapeutics by 25.2% in the third quarter. Morgan Stanley now owns 356,655 shares of the biotechnology company’s stock valued at $2,068,000 after purchasing an additional 71,860 shares during the period. Geode Capital Management LLC increased its stake in shares of Trillium Therapeutics by 164.0% in the fourth quarter. Geode Capital Management LLC now owns 26,627 shares of the biotechnology company’s stock worth $45,000 after buying an additional 16,541 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of Trillium Therapeutics in the fourth quarter worth $43,000. Finally, Two Sigma Investments LP bought a new stake in shares of Trillium Therapeutics in the fourth quarter worth $35,000. Institutional investors and hedge funds own 39.36% of the company’s stock.

Shares of Trillium Therapeutics stock traded up $0.02 during trading on Friday, hitting $0.69. 1,189,813 shares of the stock were exchanged, compared to its average volume of 828,720. The firm has a market capitalization of $9.11 million, a P/E ratio of -0.29 and a beta of 2.29. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.56 and a current ratio of 3.56. Trillium Therapeutics has a 12 month low of $0.51 and a 12 month high of $7.00.

About Trillium Therapeutics

Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides.

Recommended Story: Why are trading ranges significant?

Get a free copy of the Zacks research report on Trillium Therapeutics (TRIL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.